Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...